Announcement video posted to nova.bio, 12 March 2169 ES. Transcript below. Runtime 11:42. Presenter: Dr. Amelia T. Murphy, founder and chief scientific officer, Nova Biosciences.
[Open on Dr. Murphy, seated, no set beyond a dark wall. She is ninety-four years old and looks forty. No title card appears before she speaks.]
MURPHY: You are watching a ninety-four-year-old woman. The camera does not believe it either. That has been the product, and it has been honest, and it has not been enough. I want to tell you what we have learned in the forty-seven years since I started this company, and what we are building now that we know it.
[Cut to data visualization: a single human figure, then a brain in cross-section, then a heart. Text reads: THE WALL.]
MURPHY: Every one of our subscribers will die of the same thing. Not their knees, not their livers, not their hearts as organs. Their brains. The first generation of Prometheus kept the body young. Telomere attrition, epigenetic drift, senescent-cell accumulation: those were the reversible hallmarks, and we reversed them, on schedule, safely, for forty-seven years. What we never touched was the thing the body cannot reverse on its own, because the cells it happens in cannot divide and cannot be replaced.
The cells you were born with are the cells you die with. A cortical neuron is not a population; it is an individual. It is post-mitotic, which means it never divides, which means every somatic mutation it accumulates is permanent, and it accumulates them at a rate the longitudinal data has now quantified precisely. The 2166 cohort analysis puts the average cortical neuron at roughly 14,300 fixed somatic mutations by the 190-year mark, a burden the models reach by extrapolation from the living cohort. The heart is the same story: a cardiomyocyte carries a comparable burden, and it cannot divide either. The wall is not a single mutation. The wall is the accumulation of loss-of-function hits in the genes those cells cannot afford to lose, and it arrives in a range the models have been narrowing for five years: neuronal and cardiomyocyte burden fails somewhere between 150 and 200 years, and the first deaths are on the record now, in the upper range, among the people who came to us oldest.
The Luna University mortality working group named the pattern in 2167. They call it the neuroentropic cascade: progressive cognitive decline driven by accumulated somatic damage in irreplaceable neurons. The name will do. It is the great equalizer of the rich. You can buy a young body indefinitely. You cannot buy a young brain, because nobody knew how to repair what a brain accumulates. The first generation of Prometheus made everyone who could afford it identical in the one way that mattered least, and left them identical in the one way that matters most: their neurons are mortal, and their money cannot change that yet.
[Cut to the platform schematic from the 2122 filing: the protein-DNA chassis, the dual-guide editing complex, the patrol fleet. Text reads: THE INSIGHT.]
MURPHY: I want to correct something the industry has repeated for thirty years, which is that somatic mutation is an entropic process and entropy is not reversible. The second part is false. Somatic mutation is an entropic process, yes. Disorder accumulates. But the body is not a closed system. It has been repairing its own genome since before it was a body. Neurons have DNA repair machinery. It is imperfect, and it degrades with age, and for forty-seven years we treated that as a law. It is not a law. It is an engineering problem.
Entropy is not irreversible if you have a sufficiently precise repair mechanism. That sentence is the entire product. We built the precision in 2110, when Mark Spencer and I published TIGR-Tas: a nanoscale editing complex that requires two simultaneous guide-sequence matches before it acts, and that cleared prion, Huntington’s, and amyloid pathology completely in trial. The market ignored it, because Earth’s health systems already had cheaper answers. Then we built Prometheus on the same chassis, and we made a deliberate choice in the first generation that I now believe was correct and is now obsolete: the Aging Core does not edit the genome, because permanent telomerase activation is a documented route to cancer in dividing tissue. That objection does not apply to the cells this product is for. A neuron does not divide. A cardiomyocyte does not divide. Repairing a mutation in a cell that will never divide again is not oncogenic. It is maintenance.
[Cut to schematic of the Repair Core: a fleet of chassis units patrolling a neuron, each docking at a lesion site, reference strand in read position. Text reads: PROMETHEUS II — THE REPAIR CORE.]
MURPHY: Prometheus II is the second-generation payload: the Repair Core. The chassis is unchanged, because the chassis was always right. The guidance is the same, the strand-displacement logic is the same, the dual-guide recognition is the same, and that last part is the whole point. This is not a general-purpose machine. It is a sequence-specific machine, and it does exactly one job, continuously, for the life of the treatment cycle: it patrols post-mitotic cells, identifies deleterious somatic mutations by their deviation from a reference sequence, and repairs them in place.
The reference sequence comes from the patient. Your own hematopoietic stem cells carry the most conserved archive of your germline sequence the body still holds, and we sequence it fresh at the start of every cycle. The cell we repair is the cell you have. We do not replace neurons. There is no download, no copy, no transfer, no new tissue. The neuron that remembers your name is the neuron we maintain. Nothing in this platform is consciousness transfer, and nothing in it is replacement. If we cannot maintain the cell that is yours, we do nothing at all.
The barrier that stopped the first generation at the blood-brain barrier was delivery, and delivery was solved in 2164: the Repair Core crosses in the same temporary-permeabilization window the Disease Core always required, and the patrol fleet is resident in the parenchyma for the full cycle. The fleet does not need to be lucky once, which is the argument I know is being made about nanobots in another program, and it is a good argument. It does not apply here, for the reason I just gave: the Repair Core is not a general-purpose cascade waiting to fire at the wrong moment. It is a specific-task system with a specific reference, and when it fails, it fails on one lesion, not on a thaw.
[Cut to a plain chart. Text reads: THE CEILING. Two bars: 200. The bar on the right is labeled 600.]
MURPHY: Now the honest part, because you will not hear it from the marketing copy and you deserve it from me. The Repair Core is not one hundred percent efficient. Sustained correction fidelity in the extended trial cohort is 99.7 percent per lesion, and that number will not meaningfully improve, because it is set by the physics of recognition, not by our effort. Ninety-nine point seven percent of a lifetime’s mutations repaired is still thousands of lesions per neuron left standing, and those residuals compound with every cycle. The machinery itself degrades with use, and we repair it with the same machinery, which is a recursion with a limit. And the reversible hallmarks we solved in the first generation are not the only hallmarks that exist. We have doubled the ceiling, not removed it. The models put the functional ceiling of Prometheus II somewhere between 400 and 600 years, driven by exactly the compounding I just described: residual mutation burden, repair-machine degradation, and hallmarks we have not yet named. Our public claim is 300 to 500 years, because a claim that survives contact with the actuarial department is worth more than a claim that does not, and because “we’ve doubled the ceiling” is a stronger sentence than “live forever.” Live forever is a slogan. Doubled is a number.
[Cut to Murphy, same seat. She looks at the camera and does not look away.]
MURPHY: Rollout begins this quarter at all seven licensed stations, Hayat, Rafah, and Shifa classes, Earth and system-wide, with the first three annual cycles bundled into existing Prometheus subscriptions; new subscriptions are 41,000 UN Credits per annual cycle thereafter, and the pricing schedule for converted subscribers will be published with the rollout. The first Repair Core deployments are not in the stations. They are in me. I have been my own longest-running human trial for forty-seven years, and I am now the first patient of the second generation. My neurons are being repaired as I speak to you, and I intend to be here, in this seat, looking forty and telling you the truth about the next one, when we double the ceiling again.
We have doubled the ceiling. We intend to keep doubling it.
[End card: nova.bio / prometheus-ii. Music, no voice-over.]
See Also
- Nova Biosciences — Internal Technical Dossier: Project Prometheus (2122) — the first-generation engineering record this announcement draws on
- LIN: Dr. Amelia T. Murphy on TIGR-Tas Nanobots (2124) — public origin of the platform
- LIN Sponsored Feature: Dr. Amelia T. Murphy on Twenty-Six Years of Looking Thirty (2148) — the station network before Prometheus II
- The Peer Review — The Cells: Twelve Years Asleep (2167) — the cryosleep cascade argument Murphy answers here, and the Nova v. Dome 4 suit over the same architecture
- The Peer Review — The Cells: Biomedicine Overview (2155) — the chiral nanobot cryosleep architecture under litigation
Sources
- Nova Biosciences announcement video, nova.bio (12 March 2169 ES)
- Murphy & Spencer, “TIGR-Tas: Targeted Nanoscale Gene-Editing Complex for Prion, Huntington’s, and Amyloid-Associated Neurodegeneration” (2110)